Salman Hyder and his team found that combining a cancer therapy, which activates mutant p53 and is currently under a clinical trial, with a second drug therapy that helps suppress tumor blood vessels found in cancer cells, can help significantly reduce the spread of breast cancer tumors while also causing cancer cell death.
Figure 1: APR-246 and 2aG4 Combination Therapy Affects Tumors
Figure 1: Shows examples of tumors in situ at the end of treatment in the four left panels - and an example of complete tumor regression in the right panel. Thus, treatment with APR-246 alone or in combination with 2aG4 effectively limited the growth of and completely eradicated some tumors. Credit: Dove Press